Ed Miseta

Ed Miseta



Ed Miseta is chief editor for the website Clinical Leader, executive editor for Life Science Leader magazine, conference chair for Clinical Leader Forum, and host of Clinical Leader Live. Ed studied Business Economics at The Pennsylvania State University and also holds a Master’s degree in Business Administration. Ed has been a writer for more than 12 years and has been covering clinical research since January 2013. Ed spent 10 years in banking and investments and also taught economics at Penn State for 8 years. In his current position, Ed interviews clinical executives from pharmaceutical and biotech companies and shares their insights with readers. His primary focus is on best practices, challenges faced and overcome, clinical trends, partnering, and implementing new technologies. He has also moderated numerous speaker panels at industry conferences and trade shows.

ARTICLES BY ED MISETA

  • Adaptimmune Enters Unchartered Waters With SPEARHEAD-1 Trial

    I recently spoke to Adaptimmune CEO Adrian Rawcliffe to learn more about the company’s pipeline in its entirety, the ongoing SPEARHEAD-1 trial, and being at the forefront of cell therapy trials.
  • Why Astellas And Adaptimmune Are Partnering On STEM-Cell Therapies

    One of the greatest hurdles an immune system faces when fighting cancer is that it can’t see the tumors. Because cancer cells look a lot like a person’s own cells, it is difficult for the immune system to recognize tumors as something it should attack.
     
  • Covid-19 Hastens Embrace Of Virtual Trials

    The COVID-19 pandemic is making clinical trials difficult for sponsors, sites, and patients. But will the changes needed to protect patients finally make virtual trials a reality?
  • GlobalData: COVID-19 Will Cause Clinical Trials To Sputter

    The impact of the COVID-19 pandemic on clinical trials will be significant. A recent note from GlobalData shines a light on the impact COVID-19 will have on clinical trials. GlobalData interviewed 10 trial experts who noted the pandemic is already extensively impacting studies.
  • Clinical Trials And COVID-19: Don’t Attempt To Do It Alone

    As the COVID-19 virus continues to wreak havoc across the U.S. and the world, almost no segment of the economy has been spared its impact. That is certainly true of clinical trials conducted by the pharmaceutical industry.
  • Lilly Slams The Brakes On New Clinical Trial Activity

    Conducting clinical trials during the COVID-19 pandemic is no easy task. Recognizing this unfortunate change in events caused by COVID-19, Eli Lilly and Company has made the difficult decision to delay most new clinical study starts and pause enrollment in most ongoing studies.
  • AdventHealth Recruits 10,000 Patients For WholeMe DNA Clinical Trial

    In late 2018, AdventHealth funded and developed a new center for genomic health and personalized medicine. The first genomics project AdventHealth decided to undertake is WholeMe, a clinical trial that will sequence the DNA of 10,000 Floridians.
  • FDA Releases Guidance On Conduct Of Trials During COVID-19 Pandemic

    The FDA has released guidance for industry, investigators, and IRBs on the conduct of clinical trials during the COVID-19 pandemic. The agency issued the guidance to provide general considerations to assist sponsor companies with protecting the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing the risks to trial integrity during the pandemic.
  • How One Small Biotech Is Changing The Fight Against Cancer

    Intensity Therapeutics is preparing to kill tumors in a way that has not been attempted before. That effort is also causing challenges with patient recruitment and trial end points.
  • Belong.Life Creates World's Largest Cancer Social Network

    The lack of an information source for cancer patients prompted Irad Deutsch to found Belong.Life alongside CEO Eliran Malki. Today Deutsch is CTO of the organization, which is billed as the world’s largest cancer social network.
More From Ed Miseta